RT Journal Article
SR Electronic
T1 COVID 19: An SEIR model predicting disease progression and healthcare outcomes for Pakistan
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.29.20116517
DO 10.1101/2020.05.29.20116517
A1 Ahmad Khan, Ejaz
A1 Umar, Maida
A1 Khalid, Maryam
YR 2020
UL http://medrxiv.org/content/early/2020/05/29/2020.05.29.20116517.abstract
AB Background Recent pandemic of the Noval Coronal Virus (COVID 19) has claimed more than 200,000 lives and about 3.8 million infected worldwide. Countries are being gradually exposed to its devastating threat without being properly prepared and with inadequate response. COVID 19’s first two cases were reported in Pakistan on February 26, 2020. We present a model depicting progression of epidemiology curve for Pakistan with and without interventions in view of its health system’ response capacity in near future.Methodology We used a modified compartmental epidemiological SEIR model to describe the outbreak of COVID-19 in Pakistan including the possibility of asymptomatic infection and presymptomatic transmission. The behavior of the dynamic model is determined by a set of clinical parameters and transmission rate.Results We estimated that in the absence of a set of proven interventions, the total susceptible population would be 43.24 million, exposed individuals would be almost 32 million, asymptomatic cases would be 13.13 million, mildly infected 30.64 million, severely infected slightly more than 6 million and critical cases would be around 967,000 in number. By that time, almost 760,000 fatalities of infected critical would have taken place. Comparing with the healthcare capacity of Pakistan, if we could “flatten the curve” to a level below the dashed grey line, the healthcare system will be capable of managing the cases with ideal healthcare facilities, where the grey line representing the healthcare capacity of Pakistan. With the intervention in place, the number of symptomatic infected individuals is expected to be almost 20 million.Conclusion We consider the impact of intervention and control measures on the spread of COVID-19 with 30% reduction in transmission from mild cases in case a set of interventions are judiciously in place to mitigate its impact.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialOur study was a modeling exercise and NOT a clinical TrialFunding StatementWE declare that we received no funding whatsoever for conducting this studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB approval was not required as the study used secondary published data and assumptions for modelling purposes.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available in the manuscript and attached figures.